Clinical Trials Directory

Trials / Unknown

UnknownNCT04836611

Cannabinoides Concentrations and Hyperemesis Syndrom Occurrence in Regular Cannabis Consumer (CANEMESE)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Poitiers University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Cannabinoide Hyperemesis Syndrom (CHS) is defined as a recurrent syndrome of intractable vomiting that occurs in chronic cannabis consumers. The diagnosis is linked to clinical criteria only. The physiopathology of CHS is unknown and we observe an increase of cases with this syndrom since 2016 (Schreck et al., 2018). The aim of this study is to investigate the involvement of exogenous cannabinoids concentrations in chronic cannabis users in the occurrence of CHS.

Conditions

Interventions

TypeNameDescription
PROCEDURE1 blood sample2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire

Timeline

Start date
2021-07-01
Primary completion
2023-06-30
Completion
2023-06-30
First posted
2021-04-08
Last updated
2021-10-06

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04836611. Inclusion in this directory is not an endorsement.